[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641172":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":11,"responsibleParty":35,"collaborators":11,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":11,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":46,"maxAge":11,"enrollmentInfo":47,"targetDuration":11,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":63,"whyStopped":11,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":11},{"fullName":5,"class":6},"Helwan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intraoperative continuous infusion (CI) of cefazolin","EXPERIMENTAL",null,[13],"Drug: Cefazolin 2 g Infusion",{"label":15,"type":16,"description":11,"interventionNames":17},"Intermittent (INT) cefazolin","ACTIVE_COMPARATOR",[18],"Drug: Cefazolin 2 GM Injection",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Cefazolin 2 g Infusion","To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Cefazolin 2 GM Injection","To evaluate the effectiveness of intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Heba A Abdeen","CONTACT","0201003403231","hebabdeen89@gmail.com",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Hebatallah Ali Abdeen","Principal Investigator","100641172","phase-4-continuous-infusion-versus-intermittent-iv-bolus-of-cefazolin-prevention-of-surgical-site-infection-during-cabg-surgeries-in-egyptian-patients-100641172",false,"NCT07658378","Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During CABG Surgeries in Egyptian Patients.","Inclusion Criteria:\n\n* Cardiothoracic ICU-admitted patients who underwent CABG on CPB.\n\nExclusion Criteria:\n\n* Patients who require reoperation within 30 days.\n* Immunosuppressant patients.\n* Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.\n* Pregnancy or breastfeeding.\n* Patients who refused to sign the informed consent.","ALL","18 Years",{"count":48,"type":49},100,"ESTIMATED","INTERVENTIONAL",[52],"PHASE4","A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population.\n\nEligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).",[55],"Surgical Site Infection (SSI)",[57,58,59,60,61,62],"cefazolin","continuous infusion","intermittent","surgical site infection","surgical prophylaxis","CABG","NOT_YET_RECRUITING","2026-06-19",{"date":66,"type":67},"2026-06-24","ACTUAL",{"date":69,"type":49},"2026-07-01",{"date":71,"type":49},"2026-12-31",{"name":5,"class":6}]